Pan, Xiaoli
Pan, Yujia
Su, Yapeng
Xu, Yue
Du, Jing
Cheng, Hongcheng
Li, Guideng
Funding for this research was provided by:
National Natural Science Foundation of China (32571074 and 32300764)
National Natural Science Foundation of China (32525028 and 32270994)
Basic Research Program of Jiangsu (BK20230280)
Basic Research Program of Jiangsu (BK20250003)
CAMS Innovation Fund for Medical Sciences (2025-I2M-TS-15)
CAMS Innovation Fund for Medical Sciences (2021-I2M-1-047, 2021-I2M-1-061, 2022-I2M-2-004, 2023-I2M-2-010, 2023-I2M-QJ-019, 2024-I2M-ZD-009, and 2025-I2M-GCC-006)
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0520600)
Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2021-RC310-014 and 2024-JKCS-15)
Article History
Received: 21 October 2025
Revised: 17 November 2025
Accepted: 21 November 2025
First Online: 14 January 2026
Change Date: 31 January 2026
Change Type: Update
Change Details: The original online version of this article was revised: The Data availability section is corrected.
Declarations
:
: This study involving all the mice were kept in a specific-pathogen-free facility, and all animal experiments were performed with the approval of the Institutional Animal Care and Use Committee (IACUC) of Suzhou Institute of Systems Medicine (ISM-IACUC-0151-R). All tumor burdens did not exceed the permission of the Institutional Animal Care and Use Committee of Suzhou Institute of Systems Medicine. Age-and sex-matched mice were assigned randomly to experimental and control groups. Human PBMCs from healthy donors were purchased from Sailybio (Shanghai, China).
: Not applicable.
: The corresponding author Guideng Li is a member of the Editorial Board of the journal Immunity & Inflammation. However, he was not involved in the peer-review or decision-making process for this manuscript. The authors declare no other competing interests.